Nexentis Technologies Inc. (NXTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nexentis Technologies Inc. (NXTS) has a cash flow conversion efficiency ratio of -0.331x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-589.24K) by net assets ($1.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Nexentis Technologies Inc. for the company's overall valuation and market capitalisation.
Nexentis Technologies Inc. - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Nexentis Technologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View NXTS stock price and chart for real-time trading data and today's change.
Nexentis Technologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nexentis Technologies Inc. ranked by their cash flow conversion efficiency. Review Nexentis Technologies Inc. (NXTS) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ellen AB (publ)
ST:ELN
|
-0.130x |
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
0.029x |
|
Yida China Holdings Ltd
STU:YC2
|
N/A |
|
Bone Biologics Corp
NASDAQ:BBLG
|
-0.132x |
|
Asia Pacific Investama Tbk PT
JK:MYTX
|
0.009x |
|
JZ Capital Partners Ltd
LSE:JZCP
|
0.125x |
|
Iofina plc
LSE:IOF
|
0.166x |
|
INFINITII AI INC.
F:Y31
|
0.085x |
Annual Cash Flow Conversion Efficiency for Nexentis Technologies Inc. (2009–2025)
The table below shows the annual cash flow conversion efficiency of Nexentis Technologies Inc. from 2009 to 2025. Also see total assets of Nexentis Technologies Inc. for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.73 Million | $-3.81 Million | -0.242x | +67.62% |
| 2024-12-31 | $4.57 Million | $-3.42 Million | -0.748x | -49.37% |
| 2023-12-31 | $6.46 Million | $-3.23 Million | -0.501x | +43.66% |
| 2022-12-31 | $5.74 Million | $-5.10 Million | -0.888x | -39.01% |
| 2021-12-31 | $6.41 Million | $-4.10 Million | -0.639x | -137.24% |
| 2020-12-31 | $-465.45K | $-798.74K | 1.716x | -44.56% |
| 2019-12-31 | $-402.12K | $-1.24 Million | 3.096x | +229.27% |
| 2018-12-31 | $211.51K | $-506.50K | -2.395x | -381.37% |
| 2017-12-31 | $-732.29K | $-623.23K | 0.851x | +9.49% |
| 2016-12-31 | $-837.46K | $-650.99K | 0.777x | +348.81% |
| 2013-12-31 | $-746.71K | $-129.33K | 0.173x | -71.63% |
| 2012-12-31 | $-886.20K | $-540.99K | 0.610x | -78.45% |
| 2011-12-31 | $-233.01K | $-660.17K | 2.833x | +175.09% |
| 2010-12-31 | $-418.36K | $-430.89K | 1.030x | -68.82% |
| 2009-12-31 | $-256.64K | $-847.77K | 3.303x | -- |
About Nexentis Technologies Inc.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model… Read more